Cyclodextrins as sustained-release carriers

Pharmaceutical Technology North America

Volumn 26, Issue 10, 2002, Pages 36-46

  Sinha, V R ^a   Nanda, Amita ^a   Kumria, Rachna ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

SOLUBILITY; STABILITY;

DRUG MOLECULES;

DRUG PRODUCTS PLANTS;

BASIC FIBROBLAST GROWTH FACTOR; BETA CYCLODEXTRIN; BUSERELIN ACETATE; CAPTOPRIL; CYCLODEXTRIN; DILTIAZEM; DRUG CARRIER; FLUFENAMIC ACID; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; MOLSIDOMINE; SALBUTAMOL; TIAPROFENIC ACID;

DELAYED RELEASE FORMULATION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG STABILITY; HYDROPHOBICITY; PHYSICAL CHEMISTRY; REVIEW; SUSTAINED RELEASE FORMULATION;

EID: 0036795590     PISSN: 15342131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. K. Uekama, F. Hiryama, and T. Irie, "Cyclodextrin Drug-Carrier Systems," Chem. Rev. 98, 2045-2076 (1998).
2. V.J. Stella and R.A. Rajewski, "Cyclodextrins: Their Future in Drug Formulation and Delivery," Pharm. Res. 14 (5), 556-567 (1997).
3. J. Szejtli, "Medicinal Applications of Cyclodextrins," Med. Res. Rev. 14 (3), 353-386 (1994).
4. K. Uekama et al., "Sustained Release of Buserelin, a Luteinizing Hormone-Releasing Hormone Agonist, from an Injectable Oily Preparation Utilizing Ethylated β-Cyclodextrin," J. Pharm. Pharmacol. 41, 874-876 (1989).
5. T. Loftsson and M.E. Brewster "Pharmaceutical Applications of CD: Drug Solubilization and Stabilization," J. Pharm. Sci. 10 (10), 1017-1025 (1996).
6. T. Irie and K. Uekama, "Pharmaceutical Applications of Cyclodextrins, Part III: Toxicological Issues and Safety Evaluation," J. Pharm. Sci. 86 (2), 147-162 (1997).
7. A.R. Hedges, "Industrial Applications of Cyclodextrins," Chem. Rev. 98, 2035-2044 (1998).
8. T. Loftsson, "Pharmaceutical Applications of β-Cyclodextrins," Pharm. Technol. Eur. 10, 20-32 (1999).
9. K. Uekama and M. Otagiri, "Cyclodextrins in Drug-Carrier Systems," Crit. Rev. Ther. Drug Carrier Syst. 3 (1), 1-40 (1987).
10. K. Uekama et al., "Ethylated β-Cyclodextrins as Hydrophobic Drug Carriers: Sustained Release of Diltiazem in the Rat," J. Pharm. Sci. 76 (8), 660-661 (1987).
11. B. Husu et al., "Inclusion Complex of Nicardipine or its Hydrochloride with β-Cyclodextrin and a Sustained-Release Pharmaceutical Preparation Containing the Same, "US Patent No. 5,079,237 (1997).
12. K. Uekama et al., "Peracylated β-Cyclodextrins as Novel Sustained-Release Carriers for a Water-Soluble Drug, Molsidomine," J. Pharm. Pharmacol. 46, 714-717 (1994).
13. K. Fukunaga et al., "Aluminium β-Cyclodextrin Sulphate as a Stabilizer and Sustained-Release Carrier for Basic Fibroblast Growth Factor," J. Pharm. Pharmacol. 46, 168-171 (1994).
14. K. Uekama et al., "O-Carboxymethyl-O-Ethylcyclomaltoheptaose as a Delayed-Release-Type Drug Carrier: Improvement of the Oral Bioavailability of Diltiazem in the Dog," Carbohydr. Res. 192, 323-330 (1989).
15. Y. Horiuchi et al., "Release Control of Theophyllin by β-Cyclodextrin Derivatives: Hybridizing Effect of Hydrophilic, Hydrophobic, and Ionizable Cyclodextrin Complexes," J. Controlled Release 15, 177-183 (1991).
16. A.K. Banga and Y.W. Chien, "Systemic Delivery of Therapeutic Peptides and Proteins," Int. J. Pharm. 48, 15-50 (1988).
17. K. Nakanishi et al., "Sustained Release of Flufenamic Acid from a Drug-Triacetyl-β-Cyclodextrin Complex," Biol. Pharm. Bull. 20 (1), 66-70 (1997).
18. M. Umemura et al., "Effect of Diethyl-Beta-Cyclodextrin on the Release of Nitroglycerin from Formulations," Drug. Des. Deliv. 6 (4), 297-310 (1990).
19. F. Hirayama et al., "Utlization of Diethyl-β-Cydodextrin as a Sustained-Release Carrier for Isosorbide Dinitrate," J. Pharm. Sci. 77 (3), 233-236 (1998).
20. R. Nagashima and T. Hirano, "Selective Binding of Sucralfate to Ulcer Lesion, Part I: Experiments in Rats with Acetic Acid-Induced Gastric Ulcer Receiving Unlabeled Suralfate," Arzeim. Forsch. 30, 80-83 (1980).
21. F. Hirayama and K. Uekama, "Cylodextrins-Based Controlled Drug-Release System," Adv. Drug Deliv. Dev. 36, 125-141 (1999).
22. Y. Ikeda et al., "Controlled Release of Water-Soluble Drug, Captopril, by a Combination of Hydrophilic and Hydrophobic Cyclodextrin Derivatives," J. Controlled Release 66, 271-280 (2000).
23. M. Vakiley, F. Khorasheh, and F. Jamali, "Dependency of Gastrointestinal Toxicity on Release Rate of Tiaprofenic Acid: A Novel Pharmacokinetic-Pharmacodynamic Model," Pharm. Res. 16 (1), 123-129 (1999).
24. K. Uekama et al., "In Vitro and In Vivo Evaluation of Delayed-Release Behavior of Diltiazem from its O-Carboxymethyl-O-Ethyl-β-Cyclodextrin Complex," J. Controlled Release 25, 99-109 (1993).
25. V.R. Sinha and R. Kumria, "Colonic Drug Delivery: Prodrug Approach," Pharm. Res. 18, 557-564 (2001).
26. T. Horikawa, F. Hirayama, and K. Uekama, "In Vivo and In Vitro Correlation for Delayed-Release Behavior of a Molsidomine/O-Carboxymethyl-O-Ethyl-β-Cyclodextrin Complex in Gastric Acidity-Controlled Dogs," J. Pharm. Pharmacol. 47, 124-127 (1995).